Physician profile
Mary E Cox
NPI 1649763632
$495.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.35 · 2020: $157 · 2021: $278.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $90.74 | 2019-2021 | |
| Abbott Laboratories | $52.20 | 2020-2021 | |
| Gilead Sciences, INC. | $46.77 | 2021 | |
| Novo Nordisk INC | $43.20 | 2020-2021 | |
| Pfizer INC. | $43.07 | 2021 | |
| Lilly USA, LLC | $41.54 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $32.78 | 2019-2020 | |
| Daiichi Sankyo INC. | $31.69 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.41 | 2019 | |
| Janssen Scientific Affairs, LLC | $15.35 | 2020 | |
| Coopersurgical, INC. | $15.09 | 2019 | |
| Dexcom, INC. | $15.06 | 2021 | |
| Ibsa Pharma INC. | $14.52 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.